TY - GEN
T1 - Assessment of Serum Creatinine and Serum Sodium Prognostic Potential in Heart Failure Patients Using Machine Learning
AU - Alyounis, Sona
AU - Khandoker, Ahsan
AU - Stefanini, Cesare
AU - Hadjileontiadis, Leontios
N1 - Publisher Copyright:
© 2024 IEEE.
PY - 2024
Y1 - 2024
N2 - Heart failure (HF) is the leading etiology for hospital admissions and ranks among the foremost contributors to mortality. This complex clinical syndrome with various phenotypes is categorized by left ventricle ejection fraction levels (LVEF), namely preserved (HFpEF), mid-range (HFmEF), and reduced (HFrEF). This study investigates the prognostic impact of serum creatinine and serum sodium levels in HF patients across these three classes using machine learning tools. A comprehensive dataset of HF patients' medical records including serum sodium and serum creatinine was utilized. Machine learning regression models were employed to predict the LVEF levels. Additionally, classification models were implemented to categorize patients into HFpEF, HFmEF, and HFrEF classes. Regression analyses revealed the predictive capabilities of serum sodium and serum creatinine in estimating the progression of HF severity. Furthermore, classification models successfully differentiated between the three EF classes, providing valuable insights into the classification patterns of HF patients based on these biomarkers. The results demonstrated the significance of serum sodium serum creatinine as prognostic markers in HF, and this contributes to a more nuanced approach to HF management, paving the way for targeted interventions and improved patient outcomes. Moreover, this study highlights the potential of machine learning techniques to enhance risk stratification and classification in HF patients, enabling personalized prognostication and treatment strategies.
AB - Heart failure (HF) is the leading etiology for hospital admissions and ranks among the foremost contributors to mortality. This complex clinical syndrome with various phenotypes is categorized by left ventricle ejection fraction levels (LVEF), namely preserved (HFpEF), mid-range (HFmEF), and reduced (HFrEF). This study investigates the prognostic impact of serum creatinine and serum sodium levels in HF patients across these three classes using machine learning tools. A comprehensive dataset of HF patients' medical records including serum sodium and serum creatinine was utilized. Machine learning regression models were employed to predict the LVEF levels. Additionally, classification models were implemented to categorize patients into HFpEF, HFmEF, and HFrEF classes. Regression analyses revealed the predictive capabilities of serum sodium and serum creatinine in estimating the progression of HF severity. Furthermore, classification models successfully differentiated between the three EF classes, providing valuable insights into the classification patterns of HF patients based on these biomarkers. The results demonstrated the significance of serum sodium serum creatinine as prognostic markers in HF, and this contributes to a more nuanced approach to HF management, paving the way for targeted interventions and improved patient outcomes. Moreover, this study highlights the potential of machine learning techniques to enhance risk stratification and classification in HF patients, enabling personalized prognostication and treatment strategies.
KW - ejection fraction
KW - heart failure
KW - machine learning
KW - serum creatinine
KW - serum sodium
UR - https://www.scopus.com/pages/publications/85214988281
U2 - 10.1109/EMBC53108.2024.10782107
DO - 10.1109/EMBC53108.2024.10782107
M3 - Conference contribution
C2 - 40039648
AN - SCOPUS:85214988281
T3 - Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS
BT - 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBC 2024 - Proceedings
PB - Institute of Electrical and Electronics Engineers Inc.
T2 - 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBC 2024
Y2 - 15 July 2024 through 19 July 2024
ER -